Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates

Italian Journal of Pediatrics

Mario De Curtis²  Flavia Ventriglia²  Rosalia Ferro²  Maria Giulia Conti²  Erica Bacchio²  Antonella Scipione²  Francesca Conte²  Gianluca Terrin¹ 

[1] Department of Gynecology-Obstetrics and Perinatal Medicine, University “La Sapienza”, Viale del Policlinico 155, 00161 Rome, Italy;Department of Pediatrics, University “La Sapienza”, Rome, Italy

关键词: Indomethacin;    Ibuprofen;    COX-inhibitors;    Paracetamol;    Patent ductus arteriosus;   

Others  :  804943
DOI  :  10.1186/1824-7288-40-21

 received in 2013-12-06, accepted in 2014-02-16,  发布年份 2014

【 摘 要 】

Inhibitors of the cyclo-oxygenase component of prostaglandin-H₂ synthetase, namely indomethacin and ibuprofen, are commonly used in the treatment of hemodynamically significant patent ductus arteriosus. These drugs are associated with serious adverse events, including gastrointestinal perforation, renal failure and bleeding. The role of paracetamol, an inhibitor of the peroxidase component of prostaglandin-H₂ synthetase, has been proposed for the treatment of patent ductus arteriosus. We report a series of 8 neonates (birth weight: 724 ± 173 g; gestational age: 26 ± 2 weeks) treated with paracetamol for a hemodynamically significant patent ductus arteriosus, because of contraindications to ibuprofen or indomethacin. Successful closure was achieved in 6 out of 8 babies (75%). Median ductal diameter was significantly reduced after treatment (from 1.2 mm, range 1.0-2.5 mm to 0.6 mm, range 0.0-2.5 mm, p = 0.038). No adverse or side effects were observed during treatment. On the basis of these results, paracetamol could be considered a promising and safe therapy for the treatment of patent ductus arteriosus in neonates.

【 授权许可】

   
2014 Terrin et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hamrick SE, Hansmann G: Patent ductus arteriosus of the preterm infant. Pediatrics 2010, 125(5):1020-1030.
• [2]Clyman RI: Mechanisms regulating the ductus arteriosus. Biol Neonate 2006, 89(4):330-335.
• [3]Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF: The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacol 2013, 21(3):201-232.
• [4]Van Overmeire B, Smets K, Lecoutere D, Van De Broek H, Weiler J, De Groote K, Langhendries JP: A comparison of ibuprofen and indhomethacin for closure of patent ductus arteriosus. N Engl J Med 2000, 343(10):674-681.
• [5]Ohlsson A, Walia R, Shah SS: Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane database Syst Rev 2013, 30(4):CD003481.
• [6]Fujii AM, Brown E, Mirochnick M, O’Brien S, Kaufman G: Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol 2002, 22(7):535-540.
• [7]Shorter NA, Liu JY, Mooney DP, Harmon BJ: Indomethacin-associated bowel perforations: a study of possible risk factors. J Pediatr Surg 1999, 34(3):442-444.
• [8]Bagnoli F, Rossetti A, Messina G, Mori A, Casucci M, Tomasini B: Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. J Matern Fetal Neonatal Med 2013, 26(4):423-429.
• [9]Erdeve O, Sarici SU, Sari E, Gok F: Oral-ibuprofen-induced acute renal failure in a preterm infant. Pediatr Nephrol 2008, 23(9):1565-1567.
• [10]Akima S, Kent A, Reynolds GJ, Gallagher M, Falk MC: Indomethacin and renal impairment in neonates. Pediatr Nephrol 2004, 19(5):490-493.
• [11]Kanmaz G, Erdeve O, Canpolat FE, Oğuz SS, Uras N, Altug N, Greijdanus B, Dilmen U: Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus. Eur J Clin Pharmacol 2013, 69(5):1075-1081.
• [12]Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D: Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics 2011, 128(6):e1618-e1621.
• [13]Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, Dilmen U: Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology 2013, 103:165-168.
• [14]Yurttutan S, Oncel MY, Arayıcı S, Uras N, Altug N, Erdeve O, Dilmen U: A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med 2013, 26(8):825-827.
• [15]Oncel MY, Yurttutan S, Uras N, Altug N, Ozdemir R, Ekmen S, Erdeve O, Dilmen U: An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed 2013, 98(1):F94.
• [16]Sinha R, Negi V, Dalal SS: An interesting observation of PDA closure with oral paracetamol in preterm neonates. J Clin Neonatol 2013, 2(1):30-32.
• [17]Tekgunduz KS, Ceviz N, Demirelli Y, Olgun H, Caner I, Sahin IO, Yolcu C: Intravenous paracetamol for patent ductus arteriosus in premature infants - a lower dose is also effective. Neonatology 2013, 104(1):6-7.
• [18]Ozdemir OM, Doğan M, Küçüktaşçı K, Ergin H, Sahin O: Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation. Pediatr Cardiol 2013. [Epub ahead of print]
• [19]Alan S, Kahvecioglu D, Erdeve O, Atasay B, Arsan S: Is paracetamol a useful treatment for ibuprofen-resistant patent ductus arteriosus? Neonatology 2013, 104(3):168-169.
• [20]Roofthooft DW, van Beynum IM, Helbing WA, Reiss IK, Simons SH: Paracetamol for ductus arteriosus closure: not always a success story. Neonatology 2013, 104(3):170.
• [21]Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H: Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One 2013, 8(11):e77888.
• [22]Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, Canpolat FE, Dilmen U: Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants. A randomized controlled trial. J Pediatr 2013, (13):01394-2. doi: 10.1016/j.jpeds.2013.11.008. [Epub ahead of print]
• [23]McNamara PJ, Sehgal A: Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007, 92(6):F424-F427.
• [24]Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR: Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006, 117(4):1113-1121.
• [25]Dani C, Bertini G, Corsini I, Elia S, Vangi V, Pratesi S, Rubaltelli FF: The fate of ductus arteriosus in infants at 23-27 weeks of gestation: from spontaneous closure to ibuprofen resistance. Acta Paediatr 2008, 97(9):1176-1180.
• [26]Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI: Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007, 151(6):629-634.
• [27]Van der Westhuizen J, Kuo PY, Reed PW, Holder K: Randomised controlled trial comparing oral and intravenous paracetamol (acetaminophen) plasma levels when given as preoperative analgesia. Anaesth Intensive Care 2011, 39(2):242-246.
• [28]Echtler K, Stark K, Lorenz M, Kerstan S, Walch A, Jennen L, Rudelius M, Seidl S, Kremmer E, Emambokus NR, von Bruehl ML, Frampton J, Isermann B, Genzel-Boroviczény O, Schreiber C, Mehilli J, Kastrati A, Schwaiger M, Shivdasani RA, Massberg S: Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med 2010, 16(1):75-82.
• [29]Clyman R, Chemtob S: Vessel remodeling in the newborn: platelets fill the gap. Nat Med 2010, 16(1):33-35.
• [30]Strauss RG: Anaemia of prematurity: pathophysiology and treatment. Blood Rev 2010, 24(6):221-225.
• [31]Vandenberg KA: Individualized developmental care for high risk newborns in the NICU: a practice guideline. Early Hum Dev 2007, 83(7):433-442.